Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Current Valuation Ratios
| Eli Lilly & Co. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | Health Care | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||
| Current share price (P) | $989.12 | ||||||||||||||||
| No. shares of common stock outstanding | 943,357,420 | ||||||||||||||||
| Growth rate (g) | 30.32% | ||||||||||||||||
| Earnings per share (EPS) | $21.88 | ||||||||||||||||
| Next year expected EPS | $28.51 | ||||||||||||||||
| Operating profit per share | $27.88 | ||||||||||||||||
| Sales per share | $69.09 | ||||||||||||||||
| Book value per share (BVPS) | $28.13 | ||||||||||||||||
| Valuation Ratios (Price Multiples) | |||||||||||||||||
| Price to earnings (P/E) | 45.21 | 92.66 | 25.60 | 17.24 | 37.45 | 21.18 | 21.86 | 15.63 | 19.47 | 17.76 | 26.04 | 29.95 | 28.02 | 27.42 | |||
| Price to next year expected earnings | 34.69 | 502.26 | 18.99 | 15.70 | 34.53 | 29.13 | 19.25 | — | 21.06 | 15.10 | 22.97 | 25.52 | 25.62 | 24.98 | |||
| Price-earnings-growth (PEG) | 1.49 | — | 0.73 | 1.76 | 4.43 | — | 1.61 | — | — | 1.01 | 1.95 | 1.73 | 3.00 | 2.81 | |||
| Price to operating profit (P/OP) | 35.48 | 25.97 | 21.74 | 12.16 | 28.86 | 17.99 | 23.18 | 13.45 | 10.62 | 22.37 | 22.54 | 28.37 | 22.16 | 21.43 | |||
| Price to sales (P/S) | 14.32 | 6.40 | 5.62 | 2.52 | 5.51 | 6.23 | 6.22 | 4.39 | 2.42 | 5.58 | 3.92 | 9.87 | 6.04 | 3.23 | |||
| Price to book value (P/BV) | 35.16 | — | 22.80 | 6.58 | 2.58 | 7.94 | 7.19 | 5.43 | 1.75 | 2.56 | 3.27 | 6.34 | 7.46 | 5.89 | |||
Based on: 10-K (reporting date: 2025-12-31).
If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.
Historical Valuation Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The valuation ratios demonstrate significant fluctuations over the five-year period. Generally, the ratios increased substantially from 2021 to 2023, followed by declines in 2024 and 2025, suggesting a period of heightened investor optimism followed by a correction or normalization.
- Price to Earnings (P/E)
- The Price to Earnings ratio experienced a dramatic increase from 40.66 in 2021 to a peak of 135.24 in 2023. This indicates a substantial increase in investor willingness to pay for each dollar of earnings. Subsequently, the ratio decreased to 77.63 in 2024 and further to 47.45 in 2025, suggesting a return towards historical norms or a reassessment of future earnings potential.
- Price to Operating Profit (P/OP)
- A similar pattern is observed in the Price to Operating Profit ratio. It rose from 35.70 in 2021 to 109.75 in 2023, mirroring the trend in the P/E ratio. The declines in 2024 (to 63.73) and 2025 (to 37.24) align with the cooling observed in the P/E ratio, indicating a consistent shift in market valuation relative to operating profitability.
- Price to Sales (P/S)
- The Price to Sales ratio also exhibited an upward trend, increasing from 8.01 in 2021 to 20.77 in 2023. While the increase was substantial, the subsequent decrease to 18.25 in 2024 and 15.03 in 2025 was less pronounced than the declines seen in the earnings-based ratios. This suggests that revenue growth remained a key valuation driver, even as earnings expectations moderated.
- Price to Book Value (P/BV)
- The Price to Book Value ratio demonstrated the most significant proportional increase, moving from 25.28 in 2021 to 65.80 in 2023. This suggests a substantial increase in the market’s assessment of the company’s intangible assets or future growth prospects relative to its net asset value. The ratio then decreased to 57.93 in 2024 and 36.91 in 2025, indicating a reduction in the premium investors were willing to pay for the company’s book value.
Overall, the period from 2021 to 2025 was characterized by a significant expansion in valuation multiples, peaking in 2023, followed by a correction in 2024 and 2025. The consistency of these trends across multiple valuation metrics suggests a broad shift in market sentiment regarding the company’s future prospects.
AI Ask an analyst for more
Price to Earnings (P/E)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 943,357,420 | 948,169,999 | 950,164,452 | 950,296,118 | 952,347,126 | |
| Selected Financial Data (US$) | ||||||
| Net income (in millions) | 20,640) | 10,590) | 5,240) | 6,245) | 5,582) | |
| Earnings per share (EPS)2 | 21.88 | 11.17 | 5.52 | 6.57 | 5.86 | |
| Share price1, 3 | 1,038.27 | 867.05 | 745.91 | 329.07 | 238.31 | |
| Valuation Ratio | ||||||
| P/E ratio4 | 47.45 | 77.63 | 135.24 | 50.08 | 40.66 | |
| Benchmarks | ||||||
| P/E Ratio, Competitors5 | ||||||
| AbbVie Inc. | 94.06 | 79.59 | 63.84 | 22.62 | 22.07 | |
| Amgen Inc. | 25.81 | 38.24 | 23.14 | 19.56 | 21.05 | |
| Bristol-Myers Squibb Co. | 17.30 | — | 12.27 | 23.97 | 20.92 | |
| Danaher Corp. | 40.93 | 38.12 | 39.09 | 25.65 | 29.94 | |
| Gilead Sciences Inc. | 21.54 | 296.57 | 16.17 | 22.68 | 12.36 | |
| Johnson & Johnson | 21.66 | 26.92 | 10.73 | 22.97 | 20.93 | |
| Merck & Co. Inc. | 16.79 | 13.49 | 893.99 | 19.21 | 14.78 | |
| Pfizer Inc. | 19.83 | 18.42 | 73.42 | 7.58 | 11.76 | |
| Regeneron Pharmaceuticals Inc. | 18.19 | 17.76 | 25.99 | 19.68 | 8.37 | |
| Thermo Fisher Scientific Inc. | 28.82 | 32.03 | 35.65 | 30.55 | 27.35 | |
| Vertex Pharmaceuticals Inc. | 31.58 | — | 30.42 | 23.02 | 26.55 | |
| P/E Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 28.98 | 45.15 | 32.80 | 20.23 | 19.27 | |
| P/E Ratio, Industry | ||||||
| Health Care | 28.31 | 38.03 | 30.62 | 21.22 | 21.55 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Data adjusted for splits and stock dividends.
2 2025 Calculation
EPS = Net income ÷ No. shares of common stock outstanding
= 20,640,000,000 ÷ 943,357,420 = 21.88
3 Closing price as at the filing date of Eli Lilly & Co. Annual Report.
4 2025 Calculation
P/E ratio = Share price ÷ EPS
= 1,038.27 ÷ 21.88 = 47.45
5 Click competitor name to see calculations.
The price to earnings (P/E) ratio exhibited significant fluctuation over the five-year period. Initially, the ratio demonstrated an increasing trend, followed by a substantial peak and subsequent decline. This analysis details these movements and their potential implications.
- Overall Trend
- The P/E ratio increased from 40.66 in 2021 to 50.08 in 2022, indicating growing investor confidence or expectations regarding future earnings. However, a dramatic increase occurred in 2023, reaching 135.24, before decreasing to 77.63 in 2024 and further declining to 47.45 in 2025. This pattern suggests a period of heightened valuation followed by a correction.
- P/E Ratio and Earnings Per Share (EPS) Relationship
- The substantial increase in the P/E ratio in 2023 coincided with a decrease in earnings per share, from US$6.57 in 2022 to US$5.52 in 2023. This suggests that the price increase outpaced earnings growth, driving the ratio higher. Conversely, the subsequent decline in the P/E ratio in 2024 and 2025 occurred alongside significant increases in EPS, reaching US$11.17 and US$21.88 respectively. This indicates that while the share price continued to rise, earnings growth began to justify the valuation.
- Share Price Dynamics
- The share price consistently increased throughout the period, moving from US$238.31 in 2021 to US$1,038.27 in 2025. The rate of increase, however, varied. The largest percentage increase in share price occurred between 2022 and 2023. The P/E ratio’s peak in 2023 suggests the market anticipated continued share price appreciation, which was partially realized in 2024, but the ratio’s subsequent decline indicates a recalibration of expectations.
In conclusion, the P/E ratio’s trajectory reflects a dynamic interplay between share price and earnings. The initial increases suggest positive market sentiment, while the peak and subsequent decline indicate a period of reassessment and a potential return to a more sustainable valuation level as earnings growth accelerated.
AI Ask an analyst for more
Price to Operating Profit (P/OP)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 943,357,420 | 948,169,999 | 950,164,452 | 950,296,118 | 952,347,126 | |
| Selected Financial Data (US$) | ||||||
| Operating income (in millions) | 26,302) | 12,899) | 6,458) | 7,127) | 6,357) | |
| Operating profit per share2 | 27.88 | 13.60 | 6.80 | 7.50 | 6.68 | |
| Share price1, 3 | 1,038.27 | 867.05 | 745.91 | 329.07 | 238.31 | |
| Valuation Ratio | ||||||
| P/OP ratio4 | 37.24 | 63.73 | 109.75 | 43.88 | 35.70 | |
| Benchmarks | ||||||
| P/OP Ratio, Competitors5 | ||||||
| AbbVie Inc. | 26.37 | 37.26 | 24.34 | 14.78 | 14.21 | |
| Amgen Inc. | 21.92 | 21.55 | 19.69 | 13.40 | 16.24 | |
| Bristol-Myers Squibb Co. | 12.20 | — | 13.53 | 18.29 | 19.84 | |
| Danaher Corp. | 31.54 | 30.56 | 35.64 | 20.97 | 25.14 | |
| Gilead Sciences Inc. | 18.29 | 85.65 | 12.05 | 14.21 | 7.76 | |
| Johnson & Johnson | 22.95 | 18.20 | 17.78 | 17.62 | 18.68 | |
| Merck & Co. Inc. | 14.44 | 11.60 | 138.56 | 15.55 | 15.39 | |
| Pfizer Inc. | 10.82 | 11.92 | 121.63 | 6.64 | 12.74 | |
| Regeneron Pharmaceuticals Inc. | 22.90 | 19.63 | 25.39 | 18.01 | 7.55 | |
| Thermo Fisher Scientific Inc. | 24.94 | 27.65 | 31.16 | 25.30 | 21.07 | |
| Vertex Pharmaceuticals Inc. | 29.92 | — | 28.74 | 17.75 | 22.35 | |
| P/OP Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 22.92 | 31.13 | 32.68 | 15.94 | 16.68 | |
| P/OP Ratio, Industry | ||||||
| Health Care | 22.12 | 26.90 | 27.48 | 16.58 | 18.20 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Data adjusted for splits and stock dividends.
2 2025 Calculation
Operating profit per share = Operating income ÷ No. shares of common stock outstanding
= 26,302,000,000 ÷ 943,357,420 = 27.88
3 Closing price as at the filing date of Eli Lilly & Co. Annual Report.
4 2025 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 1,038.27 ÷ 27.88 = 37.24
5 Click competitor name to see calculations.
The price to operating profit (P/OP) ratio exhibited significant fluctuations over the five-year period. Initially, the ratio increased, followed by a substantial rise and subsequent decline, suggesting evolving investor sentiment and performance expectations.
- Overall Trend
- The P/OP ratio demonstrated a non-linear trend. It increased from 35.70 in 2021 to 43.88 in 2022, representing a moderate expansion. A dramatic increase occurred in 2023, reaching 109.75, before decreasing to 63.73 in 2024 and further declining to 37.24 in 2025.
- Share Price
- The share price consistently increased throughout the period, moving from US$238.31 in 2021 to US$1,038.27 in 2025. This upward trajectory indicates positive market perception of the company’s value.
- Operating Profit per Share
- Operating profit per share showed an initial increase from US$6.68 in 2021 to US$7.50 in 2022, followed by a slight decrease to US$6.80 in 2023. A substantial increase was then observed in 2024 (US$13.60) and 2025 (US$27.88), indicating improved operational performance in the later years.
- P/OP Ratio Dynamics
- The peak in the P/OP ratio in 2023 coincided with a relatively stable operating profit per share and a rapidly increasing share price. This suggests that investor expectations grew at a faster rate than earnings. The subsequent decline in the P/OP ratio in 2024 and 2025, despite continued share price increases, occurred alongside significant growth in operating profit per share. This indicates that the rate of share price appreciation slowed relative to the growth in operating profitability, resulting in a lower valuation multiple.
The observed fluctuations in the P/OP ratio suggest a dynamic valuation influenced by both market sentiment and underlying operational performance. The ratio’s movement indicates a potential recalibration of investor expectations as earnings growth accelerated in the later part of the period.
AI Ask an analyst for more
Price to Sales (P/S)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 943,357,420 | 948,169,999 | 950,164,452 | 950,296,118 | 952,347,126 | |
| Selected Financial Data (US$) | ||||||
| Revenue (in millions) | 65,179) | 45,043) | 34,124) | 28,541) | 28,318) | |
| Sales per share2 | 69.09 | 47.50 | 35.91 | 30.03 | 29.74 | |
| Share price1, 3 | 1,038.27 | 867.05 | 745.91 | 329.07 | 238.31 | |
| Valuation Ratio | ||||||
| P/S ratio4 | 15.03 | 18.25 | 20.77 | 10.96 | 8.01 | |
| Benchmarks | ||||||
| P/S Ratio, Competitors5 | ||||||
| AbbVie Inc. | 6.50 | 6.04 | 5.72 | 4.61 | 4.53 | |
| Amgen Inc. | 5.66 | 4.88 | 5.78 | 5.17 | 5.10 | |
| Bristol-Myers Squibb Co. | 2.53 | 2.36 | 2.19 | 3.29 | 3.16 | |
| Danaher Corp. | 6.02 | 6.23 | 7.76 | 5.79 | 6.37 | |
| Gilead Sciences Inc. | 6.34 | 4.98 | 3.40 | 3.86 | 2.85 | |
| Johnson & Johnson | 6.16 | 4.26 | 4.43 | 4.34 | 4.66 | |
| Merck & Co. Inc. | 4.71 | 3.60 | 5.43 | 4.71 | 3.96 | |
| Pfizer Inc. | 2.46 | 2.32 | 2.61 | 2.35 | 3.15 | |
| Regeneron Pharmaceuticals Inc. | 5.71 | 5.52 | 7.84 | 7.01 | 4.20 | |
| Thermo Fisher Scientific Inc. | 4.34 | 4.73 | 4.99 | 4.73 | 5.39 | |
| Vertex Pharmaceuticals Inc. | 10.40 | 10.78 | 11.16 | 8.56 | 8.21 | |
| P/S Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 6.24 | 5.55 | 5.89 | 4.56 | 4.50 | |
| P/S Ratio, Industry | ||||||
| Health Care | 3.34 | 3.36 | 3.52 | 3.11 | 3.28 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Data adjusted for splits and stock dividends.
2 2025 Calculation
Sales per share = Revenue ÷ No. shares of common stock outstanding
= 65,179,000,000 ÷ 943,357,420 = 69.09
3 Closing price as at the filing date of Eli Lilly & Co. Annual Report.
4 2025 Calculation
P/S ratio = Share price ÷ Sales per share
= 1,038.27 ÷ 69.09 = 15.03
5 Click competitor name to see calculations.
The price-to-sales ratio exhibited a generally increasing trend from 2021 to 2023, followed by a decline in subsequent years. This analysis details the observed patterns in the provided financial information.
- Price-to-Sales Ratio (P/S)
- The P/S ratio increased from 8.01 in 2021 to 10.96 in 2022, representing a 36.8% increase. This upward movement continued into 2023, with the ratio reaching 20.77, a substantial increase of 89.6% from the prior year. However, in 2024, the P/S ratio decreased to 18.25, a decline of 13.6%. This downward trend persisted into 2025, with the ratio falling further to 15.03, representing an additional decrease of 17.6%.
- Share Price
- The share price demonstrated consistent growth throughout the observed period. From $238.31 in 2021, it increased to $329.07 in 2022 (38.1% increase), then experienced a significant surge to $745.91 in 2023 (126.9% increase). Continued growth was observed in 2024, reaching $867.05 (16.3% increase), and further increasing to $1,038.27 in 2025 (19.7% increase).
- Sales per Share
- Sales per share showed a modest increase from $29.74 in 2021 to $30.03 in 2022 (1.0% increase). The rate of increase accelerated in 2023, reaching $35.91 (19.2% increase). Further growth was observed in 2024, with sales per share reaching $47.50 (32.3% increase), and continued to rise significantly in 2025, reaching $69.09 (45.4% increase).
While the share price and sales per share consistently increased over the period, the P/S ratio’s trajectory indicates a decoupling of price and sales beginning in 2024. The initial rise in the P/S ratio suggests increasing investor confidence or expectations regarding future growth. The subsequent decline in the P/S ratio, despite continued growth in both share price and sales per share, could indicate that investors are becoming less willing to pay a premium for each dollar of sales, potentially due to changing market conditions or company-specific factors.
AI Ask an analyst for more
Price to Book Value (P/BV)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 943,357,420 | 948,169,999 | 950,164,452 | 950,296,118 | 952,347,126 | |
| Selected Financial Data (US$) | ||||||
| Total Eli Lilly and Company shareholders’ equity (in millions) | 26,535) | 14,192) | 10,772) | 10,650) | 8,979) | |
| Book value per share (BVPS)2 | 28.13 | 14.97 | 11.34 | 11.21 | 9.43 | |
| Share price1, 3 | 1,038.27 | 867.05 | 745.91 | 329.07 | 238.31 | |
| Valuation Ratio | ||||||
| P/BV ratio4 | 36.91 | 57.93 | 65.80 | 29.36 | 25.28 | |
| Benchmarks | ||||||
| P/BV Ratio, Competitors5 | ||||||
| AbbVie Inc. | — | 102.40 | 29.97 | 15.52 | 16.53 | |
| Amgen Inc. | 22.99 | 26.61 | 24.94 | 35.01 | 18.51 | |
| Bristol-Myers Squibb Co. | 6.61 | 6.98 | 3.35 | 4.88 | 4.07 | |
| Danaher Corp. | 2.82 | 3.00 | 3.47 | 3.64 | 4.16 | |
| Gilead Sciences Inc. | 8.07 | 7.36 | 4.01 | 4.90 | 3.65 | |
| Johnson & Johnson | 7.12 | 5.30 | 5.48 | 5.37 | 5.90 | |
| Merck & Co. Inc. | 5.82 | 4.99 | 8.68 | 6.07 | 5.05 | |
| Pfizer Inc. | 1.78 | 1.68 | 1.75 | 2.48 | 3.35 | |
| Regeneron Pharmaceuticals Inc. | 2.62 | 2.67 | 3.96 | 3.77 | 3.60 | |
| Thermo Fisher Scientific Inc. | 3.62 | 4.09 | 4.57 | 4.83 | 5.18 | |
| Vertex Pharmaceuticals Inc. | 6.69 | 7.24 | 6.26 | 5.50 | 6.16 | |
| P/BV Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 7.72 | 7.03 | 6.77 | 5.66 | 5.72 | |
| P/BV Ratio, Industry | ||||||
| Health Care | 6.08 | 5.99 | 5.94 | 5.26 | 5.48 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Data adjusted for splits and stock dividends.
2 2025 Calculation
BVPS = Total Eli Lilly and Company shareholders’ equity ÷ No. shares of common stock outstanding
= 26,535,000,000 ÷ 943,357,420 = 28.13
3 Closing price as at the filing date of Eli Lilly & Co. Annual Report.
4 2025 Calculation
P/BV ratio = Share price ÷ BVPS
= 1,038.27 ÷ 28.13 = 36.91
5 Click competitor name to see calculations.
The price to book value ratio exhibits significant fluctuation over the observed period. Initially, the ratio demonstrates an increasing trend, followed by a period of decline. A substantial increase is then observed before a final decrease.
- Price to Book Value (P/BV) Trend
- The P/BV ratio began at 25.28 in 2021 and increased to 29.36 in 2022, indicating a growing premium investors were willing to pay for each dollar of net asset value. A dramatic surge occurred in 2023, with the ratio reaching 65.80. This suggests a considerable shift in market perception, potentially driven by positive company developments or broader market conditions. The ratio then decreased to 57.93 in 2024, signaling a moderation in investor enthusiasm. Finally, a further decline to 36.91 in 2025 indicates a continued reduction in the premium placed on the company’s book value.
The share price experienced consistent growth throughout the period, while the book value per share also increased, though at a slower pace initially. The most substantial increase in book value per share occurred between 2024 and 2025.
- Share Price and Book Value Per Share
- The share price rose from US$238.31 in 2021 to US$1,038.27 in 2025, demonstrating a strong upward trajectory. Book value per share increased from US$9.43 in 2021 to US$28.13 in 2025, indicating growth in net assets. However, the rate of increase in share price consistently outpaced the growth in book value per share, contributing to the observed changes in the P/BV ratio.
The interplay between the increasing share price and the book value per share, particularly the accelerated growth in book value in later years, appears to have influenced the P/BV ratio’s movement, initially driving it higher and subsequently contributing to its decline as the book value caught up.
AI Ask an analyst for more